Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.

AIMS Investigators

doi:10.1016/s0140-6736(19)32518-8

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.

AIMS Investigators

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Lancet (London, England)
DOIs	https://doi.org/10.1016/s0140-6736(19)32518-8
Publication status	Published - Dec 2019
Externally published	Yes

Access to Document

10.1016/s0140-6736(19)32518-8

Cite this

@article{474c968ca2124fb3a1827a1f9da558b0,

title = "Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.",

author = "{AIMS Investigators} and Michael Mullen and XY Jin and A Child and AG Stuart and M Dodd and JA Aragon-Martin and Gaze, {David C} and A Kiotsekoglou and L Yuan and J Hu and C Foley and Van, {Dyck L} and R Knight and T Clayton",

year = "2019",

month = dec,

doi = "10.1016/s0140-6736(19)32518-8",

language = "English",

journal = "Lancet (London, England)",

}

TY - JOUR

T1 - Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.

AU - AIMS Investigators

AU - Mullen, Michael

AU - Jin, XY

AU - Child, A

AU - Stuart, AG

AU - Dodd, M

AU - Aragon-Martin, JA

AU - Gaze, David C

AU - Kiotsekoglou, A

AU - Yuan, L

AU - Hu, J

AU - Foley, C

AU - Van, Dyck L

AU - Knight, R

AU - Clayton, T

PY - 2019/12

Y1 - 2019/12

UR - http://europepmc.org/abstract/med/31836196

U2 - 10.1016/s0140-6736(19)32518-8

DO - 10.1016/s0140-6736(19)32518-8

M3 - Article

C2 - 31836196

JO - Lancet (London, England)

JF - Lancet (London, England)

ER -